Equity Profile

CPRX

Catalyst Pharmaceuticals, Inc.

Health CareBiotechnology$3.8B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Catalyst Pharmaceuticals, Inc. (CPRX) is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and revenue.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CPRX Q2-2026 Earnings Preview

Context

Company Snapshot

Catalyst Pharmaceuticals, Inc. (CPRX) is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases. With a market cap of $4 billion, its work is particularly significant in the health care sector as it addresses unmet medical needs in niche markets.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+36.69%

Avg Stock Reaction

+0.67%

Last Quarter Recap

In Q1-2026, Catalyst Pharmaceuticals reported an EPS of $0.79, significantly exceeding expectations by 36.21%. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Continue focusing on the development of therapies for rare diseases.
Maintain strong operational efficiency to support profitability.
Provide updates on the status of ongoing clinical trials.

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Catalyst's upcoming earnings report, especially given its strong EPS performance in recent quarters.

Bull Case

If the company continues to beat EPS expectations and provides positive updates on its product pipeline, it could drive significant investor confidence and stock price appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing updates on its product pipeline, it could lead to a decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS figure for Q2-2026, and how does it compare to previous quarters?

Given the company's strong track record of beating EPS estimates, this figure will be critical in determining market sentiment post-earnings.

What updates will be provided regarding the product pipeline and ongoing clinical trials?

Investors will be keen to understand the potential for future revenue generation from new therapies, which could significantly impact the stock's valuation.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Catalyst to exceed EPS expectations again, given its strong historical performance and focus on rare diseases.

Supporting Evidence

The company has consistently beaten EPS estimates in the past eight quarters.

Options pricing suggests a higher expected move than historical averages, indicating market uncertainty.

The lack of revenue guidance may lead to conservative estimates that could be easily surpassed.

Key Risk

If the EPS comes in above $0.80, it could challenge the current consensus and drive the stock higher.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to maintain its strong earnings performance while also advancing its product pipeline.

Bull Confirmed If

An EPS of $0.80 or higher would confirm the bull case, indicating continued profitability and operational strength.

Bear Confirmed If

An EPS below $0.60 would confirm the bear case, suggesting potential operational challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±5.68%

Historical Avg

±1.4%

Pricing rich

The options market is pricing in a significant move of approximately 5.68%, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±5.7% while CPRX has averaged ±1.4% over the last 8 prints — setup is pricing rich.

Detail

30d HV

36.4%

Calls (5K)P/C Ratio: 0.01Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.8%, with a raw directional average of +3.1% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Catalyst beats expectations, history suggests the stock could rise by around 0.67%, confirming the company's strong operational performance.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may see minimal movement as investors reassess future growth potential.

Miss

Should the company miss expectations, the average historical reaction indicates a potential decline, though specific data on misses is not available.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of clinical trials for new therapies.
2Management's outlook on revenue growth for the upcoming quarters.
3Details on operational efficiencies that may impact profitability.
4Insights into competitive positioning within the rare disease market.
5Any commentary on potential partnerships or collaborations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Catalyst Pharmaceuticals, Inc. (CPRX) is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and revenue.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CPRX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+36.69%

Avg Stock Reaction

+0.67%

Last Quarter Recap

Management Promises & Guidance

Continue focusing on the development of therapies for rare diseases.
Maintain strong operational efficiency to support profitability.
Provide updates on the status of ongoing clinical trials.

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Catalyst's upcoming earnings report, especially given its strong EPS performance in recent quarters.

Bull Case

If the company continues to beat EPS expectations and provides positive updates on its product pipeline, it could drive significant investor confidence and stock price appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing updates on its product pipeline, it could lead to a decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS figure for Q2-2026, and how does it compare to previous quarters?

Given the company's strong track record of beating EPS estimates, this figure will be critical in determining market sentiment post-earnings.

What updates will be provided regarding the product pipeline and ongoing clinical trials?

Investors will be keen to understand the potential for future revenue generation from new therapies, which could significantly impact the stock's valuation.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Catalyst to exceed EPS expectations again, given its strong historical performance and focus on rare diseases.

Supporting Evidence

The company has consistently beaten EPS estimates in the past eight quarters.

Options pricing suggests a higher expected move than historical averages, indicating market uncertainty.

The lack of revenue guidance may lead to conservative estimates that could be easily surpassed.

Key Risk

If the EPS comes in above $0.80, it could challenge the current consensus and drive the stock higher.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to maintain its strong earnings performance while also advancing its product pipeline.

Bull Confirmed If

An EPS of $0.80 or higher would confirm the bull case, indicating continued profitability and operational strength.

Bear Confirmed If

An EPS below $0.60 would confirm the bear case, suggesting potential operational challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±5.68%

Historical Avg

±1.4%

Pricing rich

The options market is pricing in a significant move of approximately 5.68%, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±5.7% while CPRX has averaged ±1.4% over the last 8 prints — setup is pricing rich.

Detail

30d HV

36.4%

Calls (5K)P/C Ratio: 0.01Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Catalyst beats expectations, history suggests the stock could rise by around 0.67%, confirming the company's strong operational performance.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may see minimal movement as investors reassess future growth potential.

Miss

Should the company miss expectations, the average historical reaction indicates a potential decline, though specific data on misses is not available.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of clinical trials for new therapies.
2Management's outlook on revenue growth for the upcoming quarters.
3Details on operational efficiencies that may impact profitability.
4Insights into competitive positioning within the rare disease market.
5Any commentary on potential partnerships or collaborations.